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Abstract
Background: Thyroid carcinoma generally responds well to treatment and spinal metastasis is an uncommon
feature. Many studies have looked at the management of spinal metastasis and proposed treatments, plans and
algorithms. These range from well-established methods to potentially novel alternatives including bisphosphonates
and vascular endothelial growth factor (VEGF) therapy, amongst others.
The purposes of this systematic review of the literature are twofold. Firstly we sought to analyse the proposed
management options in the literature. Then, secondly, we endeavoured to make recommendations that might
improve the prognosis of patients with spinal metastasis from thyroid carcinomas.
Methods: We conducted an extensive electronic literature review regarding the management of spinal metastasis
of thyroid cancer.
Results: We found that there is a tangible lack of studies specifically analysing the management of spinal
metastasis in thyroid cancer. Our results show that there are palliative and curative options in the management of
spinal metastasis, in the forms of radioiodine ablation, surgery, selective embolisation, bisphosphonates and more
recently the VEGF receptor targets.
Conclusions: The management of spinal metastasis from thyroid cancer should be multi-disciplinary. There is an
absence; it seems, of a definitive protocol for treatment. Research shows increased survival with 131I avidity and
complete bone metastasis resection. Early detection and treatment therefore are crucial. Studies suggest in those
patients below the age of 45 years that treatment should be aggressive, and aim for cure. In those patients in
whom curative treatment is not an option, palliative treatments are available.
Introduction
Thyroid cancer is uncommon, accounting for roughly
1% of all new malignant disease, about 05% of cancers
in men and 15% in women [1-4]. It affects approxi-
mately 1900 people in the UK each year, but its inci-
dence has been increasing for decades [5-8]. Much of
the rise in incidence can be explained by improved diag-
nostic methods. However, this cannot entirely explain
the upward trend [8-10].
Differentiated thyroid cancer (DTC) account for the
vast majority (90%) of all thyroid cancers and includes
papillary (70–75%) and follicular (15–20%) cancers.
Hürthle-cell cancers (2%) and insular carcinomas also
arise from follicular cells but are probably within the
spectrum from differentiated to undifferentiated.
Undifferentiated carcinomas, which are anaplastic malig-
nancies, account for <5% of thyroid cancers. They de-
rive from follicular cells. Medullary carcinoma, in
contrast, constitutes 5–10% of thyroid cancers [5,11,12].
The significance of the histological distinction relates
to the management and prognosis of the different types
of carcinomas. Differentiated carcinomas have a better
prognosis than undifferentiated, Hürthle and insular
cancers [8,11]. Medullary thyroid carcinomas arise from
the C-cells and are, therefore, aetiologically and clinic-
ally, different to follicular cancers [8,11]. There are also
other rare types of thyroid malignancies including
lymphomas and sarcomas.
In general, thyroid cancer is more prevalent in the
middle-aged or old and in females [4]. Papillary malig-
nancy typically occurs in young females and sometimes
in children, whilst Follicular malignancy predominantly
affects middle-aged females. Anaplastic thyroid cancer is
more common in the elderly [7].
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localised spread. It is known, however, to metastasize to
both lung and bone. The prognosis of papillary thyroid
cancer is good, especially in the young and if diagnosed
early. Follicular malignancy preferentially metastasises to
lung and bone. The prognosis is good if diagnosed early.
Anaplastic thyroid carcinomas are very aggressive and
locally invasive. They respond poorly to treatment and
prognosis is poor. Medullary cancer sometimes has a fa-
milial origin associated with the RET gene and can also
be part of Multiple Endocrine Neoplasia type 2 syn-
drome (MEN-2 syndrome). It is too, characterised by in-
dolence and localised spread, as well as metastasis to
different sites. It has a poor prognosis but can be treated
if found before distant spread [3,5,12,13].
In 90% of cases, thyroid carcinoma presents simply as
thyroid nodules. Rarely, the first manifestation is cervical
lymphadenopathy (5%), or distant metastasis in the
lungs, bone, liver or brain. Bony metastasis occurs in ap-
proximately 2–13% of people with thyroid malignancy;
the proportion is overwhelmingly follicular, and many of
those develop in the spine [3,13,14]. The latter are par-
ticularly debilitating as they often cause pain, fractures,
spinal cord compressions and affect mobility and quality
of life (QoL) [15]. The remission rate in bony metastasis
is 7–20% [16].
The survival rate in thyroid carcinoma is generally
good, apart for the anaplastic type. The 10-year survival
rate in DTC is 80–95%. However, this figure drops to
about 40% when distant metastasis is present [16].
The pathogenesis of thyroid carcinomas is not fully
understood. Aetiology is known only in a few rare cases
of familial papillary and medullary carcinomas, and in
some patients who have been exposed to irradiation or
radioactivity [5].
There is a pathway to diagnose thyroid cancer includ-
ing: physical exam to feel for nodules, blood tests (par-
ticularly: TSH, thyroglobulin and calcitonin levels),
ultrasound, thyroid scan with a radioactive marker. Also,
biopsy with fine needle aspiration (FNA) is helpful; how-
ever, surgery is the gold standard and the only conclu-
sive diagnostic method [4,10,17].Management of thyroid cancer
It is widely agreed in the literature that surgical resec-
tion should be the initial step in treating most thyroid
cancers [4,17-19]. Following a biopsy to determine the
histology of the tumour, a decision is made whether to
perform a lobectomy or total thyroidectomy [4,19].
Patients who have had total or near-total thyroidectomy
are required to have their serum thyroglobulin checked
no sooner than six weeks after the procedure in order to
check for recurrence.The surgery is often followed by adjuvant radioiodine
therapy (131I ablation). Following the resection of the
thyroid gland, thyroid hormone replacement therapy is
given in order to rectify the resulting hypothyroidism. It
is also thought that in high doses the replacement ther-
apy helps prevent recurrence of the cancer [19].
Chemotherapy and external radiation are also used in
the treatment albeit more rarely than the above men-
tioned treatments. External radiation is used infrequently
as palliative treatment in cases of unresectable or sec-
ondary disease [10,11,17,19].
The use of chemotherapy is more controversial. It is
generally ineffective in most types of thyroid cancers,
but it is indicated for the anaplastic type, lymphoma or
metastatic tumour. It has also been used as palliation in
end-stage disease unresponsive to irradiation and also for
progressive, symptomatic disseminated cancer [20]. The
agents used are doxorubicin and cisplatinum [11,17,19].
In most cases the treatment of thyroid carcinomas
results in long-term remission. Survival is excellent in
younger patients with recurrence more likely at extremes
of age [21,22]. However, there are still patients with poor
outcomes. They are usually the patients with metastasis
and/or advanced disease at diagnosis [11,18]. For this rea-
son, new treatment modalities are being explored.
Metastasis from thyroid cancer
DTC metastasises preferentially to bone (25%) second
only to the lung (49%) whilst synchronous spread to
lung and bone accounts for a further 15% of distant me-
tastasis of DTC. The remaining occur in other soft tis-
sues [3,23,24].
Bone metastasis occurs in 2–13% of DTC cases. They
are more prevalent in follicular cancer (7–28%) than in
papillary cancer (1.4-7%) [3]. The great majority of bone
metastasis occur in regions where blood flow is high,
such as the axial skeleton red marrow in vertebrae, ribs
and hips [3]. The spinal lesions are mostly osteolytic,
with new bone forming in response to the bone destruc-
tion [3].
The diagnostic modalities used in spinal metastasis are
different to those used in the determination of thyroid
cancer. CT and MRI scans are used to provide high reso-
lution imaging of the spine. MRI is better at differentiat-
ing soft tissue structures and, therefore, it is slightly
more sensitive at detecting bone marrow metastasis26.
Bone scintigraphy and other nuclear studies, such as
FDG-PET and SPECT, are also used for localisation of
lesions and have high sensitivity and specificity [25].
When bony metastasis is present, the 10-year survival
rate is estimated between 13% and 21%, which is roughly
equivalent to a 50% reduction compared to non-
metastasised cancer3. It is often the case that the lesion
(s) do not respond to curative treatment and palliative
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being to improve the quality of life [3].
Spinal metastasis
Bone, after the lungs and liver is the third commonest
site of metastasis [26]. Spinal metastasis is by far the
most common type of spine tumours, outnumbering pri-
mary spinal neoplasm by more than twenty-to-one [25],
and, are overwhelmingly breast, lung, prostate or renal
primaries in origin [25-27]. This owes much to their re-
spective incidence as well as their special predilection
for the vertebral column [25].
Prevalence of spinal metastasis (SM) is highest among
individuals between the 4th and 7th decade of life
[25,27,28]. Males are more likely to be afflicted; this is
thought to be reflective of the higher prevalence of lung
cancer in this group [12] and the higher prevalence of
prostate cancer relative to breast cancer in females [25].
At the time of initial diagnosis, 1%-3% of patients with
thyroid cancer have distant metastasis whereas another
7%-23% will develop distant metastasis during the
course of their disease (2,5-8,10-12). Bone metastasis is
diagnosed clinically in 2%-13% of patients with differen-
tiated thyroid cancer [29].
Well-differentiated thyroid cancers (DTC) account for
the vast majority (85–98%) of thyroid malignancies.
Bone metastasis incidence in differentiated thyroid can-
cers (DTC) is 2–13% [30,31]. Papillary thyroid cancers
(PTC) accounts for 77% of DTC and has a low incidence
of SM of 1–7% [31] whilst follicular thyroid cancer
(FTC) which accounts for 15% of all DTC has an inci-
dence of bone metastasis of 7–20% [31]. Hürthle cell
carcinomas, which accounts account for 2% of thyroid
malignancies, have the highest propensity (12%) to
metastasize to spine.
Spinal metastasis typically affect the thoracic (60–80%),
lumbar (15–30%) and cervical spine (<10%) [32-54] with
the preferred route of metastasis to the spine being via the
arterial or venous -Batson’s venous plexus - vessels result-
ing in multifocal lesions. Direct infiltration from paraspi-
nous disease or, less commonly, through the cerebrospinal
fluid [25,32] are also potential routes of metastasis. The
vertebral body (85%) [54] is the commonest site for initial
involvement; the posterior aspect of which is preferentially
involved (66%) [25]. The paravertebral spaces (10–15%)
and the epidural space (<5%) are also initial sites of meta-
static involvement [25,32,54].
Vertebral metastasis are asymptomatic and may be in-
cidental findings following routine bone scans in
patients presenting with systemic disease [32,33]. Clas-
sical clinical symptoms develop with the progression of
spinal metastatic disease and are consequences of meta-
static infiltration and/or compression of paravertebral,
osseous and neural tissue [33].Spinal canal to spinal cord ratio is smallest in the thor-
acic spine hence spinal cord compression is more com-
mon in the thoracic spine [33]. The most frequent cause
of spinal cord compression and nerve root compression
is the expulsion of metastatic tissue and/or detritus of
bone into the spinal canal or neural foramina following
metastatic infiltration and ensuing partial collapse of the
vertebral body. On infrequent occasion, metastatic tissue
may break into the spinal canal and cause spinal cord
compression without assaulting the vertebral body’s
structural integrity.
The chief presenting symptom of spinal metastasis is
pain (83–95%) [25,32]. Patients often present with loca-
lised, gradual onset pain caused by periosteal stretching
and inflammation [32]. It is invariably progressive and
unremitting in nature, often worse at night. It may im-
prove with activity and anti-inflammatory medications.
The affected area is typically tender on examination
[33].
Radicular pain, described as shooting pain, is a com-
mon compliant in SM. It is caused by impingement or
irritation of nerve roots in the intervertebral foramina,
either by direct tumour compression or via tumour
induced pathological fractures. Neuropathic pain charac-
terised by an intense, burning sensation is more com-
mon in intradural metastasis [32].
Metastatic invasion of the spinal canal occurs predom-
inantly in an anterior direction. Spreading via the poster-
ior aspect of the vertebral body [33], deficiencies in
motor functions comprise the second most common pre-
senting symptom (35–75%26) in patients with vertebral
column metastasis [32,33]. Limb weakness is a common
symptom, which is seen also on physical examination
[25].
Posterior displacement of the spinal cord and impinge-
ment against the lamina may result in sensory dysfunc-
tion [32,33]. It is a feature of advanced spinal metastatic
disease and can be accompanied by profound motor dys-
functions such as anal and urethral sphincter dysfunc-
tion and sexual malfunction [25,32].
These “red flag” signs and symptoms should prompt
SM diagnosis in thyroid cancer patients. In such
patients, a full diagnostic workup should be instigated to
ascertain the level(s) of vertebral column involvement,
spinal instability and the degree of neurological impair-
ment. These parameters influence the decision to oper-
ate or not [25,32,33].
Plain X-ray is used to identify metastatic lesion(s),
tumour mass(s) and evaluation of spinal stability [27,32].
Spinal instability is indicated by progressive deformity, sig-
nificant angulation or translocation and/or >50% involve-
ment of the vertebral body. Cervical disk space narrowing
is an important maker of vertebral collapse. Metastatic
lesions are indicated by vertebral body involvement,
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visualize pedicles [27]. X-rays are insensitive in early spinal
metastatic diagnosis, however, because a 30–50% deminer-
alisation of bone is required before lytic lesions become
apparent on radiographic film [25,27,32].
Magnetic resonance imaging (MRI) is the gold-standard
imaging modality in SM diagnosis. It renders exquisitely
detailed multiplanar imaging, allowing the visualisation of
metastatic infiltration and/or compression of paraver-
tebral, osseous and neural tissue [25,27,32]. T1- and
T2-weighted imaging as well as contrast-enhanced and
fat-suppressed studies in all three planes aid
diagnosis33.
Computed tomography (CT) imaging is an excellent
modality in assessing the osseous spine. It has a high de-
gree of accuracy (90% sensitivity, 100% specificity) [28]
in identifying metastatic lesions, vertebral destruction
and spinal stability. CT angiography is ideal in identify-
ing spinal metastasis from highly vascular primary ma-
lignancies such as thyroid cancers [32].
Bone scintigraphy is used to screen for bone metasta-
sis. Despite its documented 62–89% [25] sensitivity, itFigure 1 Flow chart illustrating search protocol.should be noted that bone scintigraphy measures abnor-
malities in bone metabolism and does not, therefore,
possess a high specificity in identifying SMs.
MRI and/or CT should be used to authenticate sus-
pected SM. Single-photon emission computed tomog-
raphy (SPECT) and fluorodeoxyglucose positron emission
tomography (FDG-PET) [25] are both superior to bone
scintigraphy and are used in surveillance of patients sus-
pected of SM. Finally biopsy under CT fluoroscopic guid-
ance is crucial in staging SM and formulating surgical
treatment plan.
The purposes of this systematic review of the literature
are twofold. Firstly we sought to analyse the proposed
management options in the literature. Then, secondly,
we endeavoured to make recommendations that might
improve the prognosis of patients with spinal metastasis
from thyroid carcinomas.
Materials and methods
A thorough electronic literature search was conducted
using online journal databases. These included PubMed,
Google Scholar, Web of Knowledge, Science Direct and
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ing, “spinal metastasis in thyroid cancer”, “management
of spinal metastasis”, “thyroid metas* spin*”. This yielded
20 studies. To supplement our research, we reviewed the
references of the literature initially found, in order to
avoid neglecting relevant articles that were missed by
our search criteria. We excluded from our initial pool of
recruited studies those that were review papers and
those articles dated pre 1990 to ensure a body of con-
temporary literature.
Articles were deemed pertinent if they described meta-
static thyroid cancer of a follicular, papillary or Hürthle
nature. We sought, particularly, studies that included a
population of patients with bone metastasis and spinal
involvement. We did not include small case reports or
studies that investigated spinal metastasis, without men-
tion of thyroid cancer because the nature of thyroid can-
cer treatment is specific. In order to attain reliably
representative results, we eliminated case reviews. The
chosen studies were selected by two independent
reviewers using the above protocol.
Results
Our search protocol refined our pool of articles to 20
[13-16,29,30,34-47], as seen in Figure 1. In this system-
atic review we focused on therapeutic management of
spinal metastasis in thyroid cancer with reference to sur-
vival time, pain management and prognostic indicators.
As a part of this review, the various parameters were
evaluated including the study design, sample size, histo-
logical type of cancer, mean age, outcome and mortality.
The characteristics of the studies can be seen in Table 1.
Our search protocol retrieved 20 studies published from
1996 to 2012 (Table 1). Studies investigated the use of
conventional and novel intervention for distant and spinal
metastasis, including radioactive iodine, surgery, selective
embolisation therapy (SET), small molecule inhibitors and
bisphosphonates. Reported outcomes included survival
rates, morbidity and prognostic factors associated with
each intervention. There were 16 retrospective cohort
studies [13,15,16,29,30,34,36,38-45,47], 1 observational
study [14], 1 prospective interventional study [35], 1 Phase
II trial [37] and 1 Phase III clinical trial [17].
Reported cases of spinal metastasis and therapeutic
modalities used can be seen in Table 2. Summary results
pertaining to the use of conventional and novel thera-
peutic modalities in treating patients with distant metas-
tasis from thyroid carcinoma can be seen in Tables 3
and 4, respectively. The population size in each study
varied considerably between studies, from Durante et al.
[30] (n = 444) to Van Tol et al. [44] (n = 11).
One of our studies, by Wells et al. [46], was a rando-
mized controlled trial, which investigated the effect of
vandetanib versus placebo, however, there were nointerventional trials comparing the effect of different
treatments of metastatic disease. Of the retrospective
trials, too, no studies sought to compare treatments.
Two studies looking at the specific use of bisphospho-
nates were Orita et al.[15] and Vitale et al.[45], although
Orita et al. had mentioned, previously, that bisphospho-
nates contribute to an improved 5-year survival (52%
with and 30% without bisphosphonate; P value = 0.11).
However, on subsequent interrogation it was found that
zolendronic acid infusion once a month, increased the
chance of avoiding skeletal-related events (SREs),
defined as bone fracture, spinal cord compression, and
hypercalcaemia, in the first 3 years post detection (50%
without bisphosphonate compared to 86% with bispho-
sphonate; P value of 0.002). This corroborated Vitale
et al.’s work that illustrated pamidronate IV infusion
once a month, for 12 months, improves the quality of
life using the FACT-G scoring system (P value = 0.0059)
[45].
Surgical intervention for bone metastasis was exam-
ined in 4 studies: Bernier et al. [34], Demura et al. [13],
Orita et al. [38] and Quan et al. [40]. Bernier et al.,
showed through multivariate analyses that complete SM
surgery was an independent prognostic indicator of
improved survival, however, this only applied to younger
patients (under 45 years of age) [34]. Demura et al., who
employed an en-bloc resection approach, reported that
the survival rate from surgery was 74% at 5 years and
25% at 10 years. The risk of local recurrence after
debulking surgery was 57% and required further surgery
at an average of 41 months, however recurrence after
total en bloc spondylectomy (TES) was 10% and this dif-
ference was statistically significant. They reported that
all patients alive at study close were neurologically pre-
served [13]. Orita et al. reported 5-year survival with
surgery of 60% compared to 37% (P value = 0.05) with
no surgery [38].
Selective Embolisation therapy (SET) therapy was
investigated in 3 studies, by Van Tol et al. [44], Eustatia
Rutten et al. [16] and, most recently, by De Vries et al.
[36]. Van Tol et al. [15] found that those who received
combined embolisation with 131-I therapy, serum Tg fell
by 88.7%, which was significantly more than the control
group 16.6%; p< 0.05. Eustatia-Rutten et al. found it
was effective at palliation in 59% of cases, with success
duration being 6.5 months alone, but for embolisations
combined with additional radioiodine or external irradi-
ation, this was increased to 15 months (P> 0.0146) [16].
Finally, De Vries et al., came to the conclusion that sur-
vival is not significantly improved, however symptoms
were reduced in 55% of procedures [36].
The impact of 131I therapy was investigated in 5 studies
[14,29,38,39,41]. Although Pittas et al. [29] did not find an
increased survival in those who were treated with 131I for
Table 1 Summary of the study characteristics
Study, year Study design End point
Bernier et al., 200135 Retrospective cohort analysis Survival and impact of treatment on survival.
Cabanillas et al., 201036 Prospective intervention Determine response and progression free survival due
to treatment with sorafenib/sunitinib
De Vries et al., 200837 Retrospective cohort analysis Determine the effect of selective embolisation on serum
thyroglobulin and symptoms
Demura et al., 201114 Retrospective cohort analysis Determine the effect of total en bloc spondylectomy on
survival and local recurrence
Durante et al., 200631 Retrospective cohort analysis Determine the response and effect on survival of
131I therapy
Eustatia-Rutten et al., 200317 Retrospective cohort analysis Determine the effect of palliative embolisation on
clinical symptoms.
Hindie í et al., 200715 Observational study To investigate the impact of early 131I-based detection
on outcome.
Kloos et al., 200938 Phase II Trial Objective response rate of VEGFR inhibitors
Orita et al., 201116 Retrospective cohort analysis Determine the efficacy of zolendronic acid on skeletal-related
events and bone metastasis from thyroid cancer
Orita et al., 201039 Retrospective cohort analysis Determine prognostic factors and analyse treatment methods
Petrich et al., 200040 Retrospective cohort analysis Determine the therapeutic outcome and side effects of
radioiodine in bone metastasis from thyroid cancer
Pittas et al., 200030 Retrospective cohort analysis Determine prognostic indicators and impact of treatment on survival
Quan et al., 201241 Retrospective cohort analysis Determine survival of patients with vertebral metastasis from
thyroid cancer
Qiu et al., 201142 Retrospective cohort analysis Determine the efficacy of 131I therapy and survival
Schlumberger et al., 199643 Retrospective cohort analysis Determine the response of bone and lung metastases to 131I
Stojadinovic et al., 200244 Retrospective cohort analysis Determine distant disease free survival and post metastatic disease
specific survival after surgery for distantly metastatic thyroid carcinoma
Van Tol et al., 200045 Retrospective cohort analysis Determine the effect of embolisation in combination with
radioiodine in terms of pain, serum T and neurological symptoms
Vitale et al., 200146 Retrospective cohort analysis Determine the impact of pamidronate on bone pain, performance
status and evaluate the degree of tumour response.
Wells et al., 201247 Phase III RCT Determine progression free survival of patients on vandetanib for
metastatic thyroid cancer
Zettinig et al., 200248 Retrospective cohort analysis Determine the role of surgery on survival of metastatic thyroid cancer
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in patients whose bony metastases show 131I uptake.
Petrich et al. [39] showed positive radioiodine uptake by
metastases significantly increased survival compared to
those individuals who had negative uptake. Orita et al.
[38] and Hindie et al. [14] provided findings that a signifi-
cant survival advantage was obtained with 131I therapy
supporting that claim. Additionally, a study by Qiu et al.
[41] found that 131I therapy was 63.9% effective at redu-
cing symptoms due to bony metastasis such as pain, and
could therefore be used as a palliative agent in patients
with multiple bone metastases.
VEGFR therapy was investigated in two studies [37,46]
in the form of sorafenib and vandetanib. Kloos et al.
[37] found that sorafenib caused stabilisation of disease
progression for greater than 6 months in 56% of patients(95% CI, 40 to 72). Wells et al. [46] investigated vandeta-
nib in the form of a phase III randomised control trial
and investigated the progression free survival (PFS) in
comparison with placebo. They found a prolonged pro-
gression free survival in the treatment group estimated
at 30.5 months, compared a PFS of 19.3 months in the
placebo group. However, 12% of patients stopped the
drug due to adverse events [46].
Discussion
Metastatic thyroid tumours cause considerable morbid-
ity [48]. They are also indicative of advanced disease and
are associated with a poor prognosis [29] and a reduc-
tion in treatment response. However, comparatively, they
have a more favourable prognosis of most tumours,
which metastasize to the spine [40,49]. Tumour invasion
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Table 2 Clinical characteristics at diagnosis of patients with spinal metastasis from thyroid carcinoma and the therapeutic strategies deployed (Continued)
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Table 2 Clinical characteristics at diagnosis of patients with spinal metastasis from thyroid carcinoma and the therapeutic strategies deployed (Continued)
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Table 2 Clinical characteristics at diagnosis of patients with spinal metastasis from thyroid carcinoma and the therape tic strategies deployed (Continued)
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Table 3 Summary results of studies that deployed conventional therapeutic modalities in patients with distant metastasis from thyroid carcinoma
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ture of the spine [40]. Compression of the cord or cauda
equina induces severe pain, paralysis and sphincter dys-
function [40,48]. Therapeutic interventions should,
therefore, target first and foremost the integrity of the
spine to prevent neurological complications. In doing so,
they may vouchsafe symptomatic control, such as pain,
paralysis and the impact these have on activities of daily
living [48].
Once spinal metastasis has been diagnosed, there are a
several modalities of treatment. Treatment can be pallia-
tive or curative. The use of radioiodine ablation therapy,
selective embolisation therapy (SET), bisphosphonates,
surgery, and small molecular therapy is being discussed
[40].
Approximately 90% of patients with spinal metastasis
experience pain [25]. The pain can be significantly de-
bilitating and interfere with quality of life. Pain, in meta-
static cancer, is managed by a multidisciplinary team;
treatments include analgesia, bisphosphonates, radio-
therapy and chemotherapy [50]. In terms of spinal me-
tastasis, intractable pain is often a surgical indication
[13], and many other treatments such as SET and radio-
iodine have been shown to reduce pain scores [44].
Radioiodine ablation therapy
Radioiodine therapy is a mainstay of thyroid cancer
management [10,19,31]. Many studies reported benefit
retrospectively. Intriguingly, Van Tol et al. [44] demon-
strated that radioiodine ablation reduces the pain rating
on a 4 point analogue scale, irrespective of whether SET
was combined, in a number of patients with spinal me-
tastasis. Radioiodine absorption is a prognostic factor in
metastatic disease [14]. Tumours, which are non-
functioning, represent an entity further down the path-
way of malignant transformation and they are resistant
to the radiation dose delivered through radioiodine se-
questration. Hindie et al. recommend that young
patients who have 131I avid metastasis, of a papillary or
follicular, well differentiated nature, should receive 131I.
Durante et al. [30] observed that once a patient achieved
a positive scan, it on average took a cumulative dose of
up to 600 mCi to achieve a negative scan. It has been
shown that a dose exceeding this value can lead to
increased risk of haematological malignancy, and salivary
gland dysfunction. They suggested, therefore, that if
patients have been treated with 600 mCi, as a cumulative
dose, deciding to re-treat should be made on an individ-
ual basis.
Selective embolisation therapy
SET represents an attractive therapy due to its induction
of rapid, albeit, transient symptom amelioration. Eustatia
Rutten et al. [16] suggested that symptomatic controland progression arrest is achievable in 59% of emboliza-
tions. In reality, however, this does not equate to 59% of
patients receiving neurological and pain benefit. They
also found that the benefit lasted a mean duration of
6.5 months suggesting that more sessions may be
required to continue to ameliorate symptoms [16].
There is evidence, albeit sparse, of its efficacy in cervical
instability [16,36]. Serum thyroglobulin (Tg) a marker of
tumour burden, was radically reduced in an a study by
Van Tol et al. in the embolisation group, (88.7% c.f.
18.6% in the control; p< 0.05). Of course, this is only a
proxy for disease. De Vries et al.[36] postulated that em-
bolisation may be beneficial in not only palliating symp-
toms, but can be used in an adjuvant setting, a form of
pre-operative embolisation to help reduce blood loss37.
Unfortunately, SET does not appear to improve survival
[16,36]. SET alone induces tissue hypoxia, a stimulus for
tumour growth. The combination of SET with radiation
therapy may confer a synergistic benefit.Surgery
The role of surgery is debatable. Quan et al. [40] sug-
gests that surgery is indicated for patients with intract-
able pain, cord compression, neurological deficit or
cervical instability [40]. Cervical metastasis can produce
pain unresponsive to medical management, which can
affect activities of daily living. In addition neurological
deficits and pathological fractures can occur due to
metastatic lesions reducing the integrity of the vertebral
bodies [50]. Metastatic cervical spine disease causing in-
stability is usually treated with anterior reconstruction
and stabilisation [51] Bernier et al. [34] reported that
surgery as a whole did not improve survival, but
complete bone metastasis (BM) resection did [34]. A fac-
tor for deciding which type of surgery patients were
given was age. Surgical treatment in the young should,
therefore, be more aggressive. Demura et al. [13] sug-
gested that total en bloc spondylectomy (TES) may pro-
vide better local control of thyroid cancer spinal
metastasis, compared with debulking surgery. Complete
resection of synchronous metastasis was associated with
increased survival [13]. The authors showed a significant
difference in the risk of local recurrence with debulking
surgery (risk of recurrence 57%, c.f. 10% with TES).
Patients who underwent complete metastasectomy had
significantly improved survival than those having pallia-
tive resection (5-year DSS, 70% vs. 30%, P value= 0.004)
[43]. This indicates, perhaps, that it is important to treat
as many metastasis burden as possible, however, this
may not always be achievable. Although, there is consid-
erable bias in this conclusion, in that those patients
whose disease is too extensive to treatment would, of
course, have a poorer survival. Kushchayev et al. [23]
Table 4 Summary results of studies that deployed novel therapeutic modalities in patients with distant metastases from thyroid carcinomas
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Figure 2 Route of transmission from thyroid to spine.
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http://www.headandneckoncology.org/content/4/1/39also mentioned percutaneous vertebroplasty for patients
who cannot be operated on but at risk of fractures.
Bisphosphonates
Bisphosphonates have shown some clinical usefulness in
metastatic bone disease in terms of symptom control.
Orita et al. [15] illustrated that skeletal related events
occurred in significantly lower frequency in patients on
zoledronic acid (3/22 patients, 14%) than without (14/28
patients, 50%; p> 0.007). Pamidronate was also effective
at pain amelioration [45], with a 31.35% reduction using
the VAS scoring. Patient tolerability was good, although
the side effect of osteonecrosis of the jaw is, unfortu-
nately, relatively high at 9% [15], though the study size
was small. Other studies have intimated that as much as
5% of the oncological patients receiving bisphosphonate
therapy for ~4.4 years develop bisphosphonate-related
osteonecrosis of the jaw (BRONJ) [52]. The authors
reported an impressive spinal cord compression reduc-
tion, although study size was small (n = 28).
Small molecules
The effect of small molecule inhibitors has revolutionised
the treatment of some cancers, and the search of molecu-
lar targets in neoplasm continues. Growth signalingpathways are implicated in tumorigenesis, especially those
of angiogenesis. Vascular endothelial growth factor recep-
tors (VEGFR) inhibitors appear not to improve progres-
sion free survival in metastatic thyroid cancer [37].
However, small study sizes have impeded research. In a
study by Kloos et al. [37], side effects prompted 52% of
patients to reduce their dose. Cabanillas et al. [35], treated
15 patients, mostly with non 131I avid disease with differ-
ent VEGFR inhibitors, notably sorafenib. Interestingly,
progression free survival was increased. It was observed
that patients whom had their SM irradiated, prior to
VEGF therapy, maintained stable bone disease, whereas
those who did not have irradiation experienced rapid pro-
gression, despite a good response of their lung metastasis
to VEGF therapy. This raises the possibility that treating
patients with (external bean radiation therapy) EBRT prior
to VEGF therapy could improve survival. This may need
to be examined in further detail.
Difficulties encountered
We encountered difficulties with regards to study selec-
tion and data extraction, contemporaneous research, study
size and consistency of protocol. We cannot claim to have
used a complete and exhaustive list of studies. Our search
results yielded a large body of research relevant to our
Figure 3 The proposed recommendations of treatment.
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http://www.headandneckoncology.org/content/4/1/39title. We cross-examined the references to add to this
body. This approach is rigorous but not consummate.
In addition, many of the papers made analysis difficult
due to the presentation of their data. Spinal metastasis
was rarely isolated as a subgroup. Indeed, many forms of
metastases were pooled for the statistics. It was, there-
fore, impossible to extract specific and valuable informa-
tion from these studies [35,37,46].
Several retrospective studies did not use contemporary
data sets. Studies, recruited by the inclusion criteria,
analysed investigation and treatment modalities in a pa-
tient pool, which was considerably dated due to some
cohorts having been accrued over decades. These studies
spanned a long period of time, during which, treatmentand investigative modalities had significantly evolved.
They, therefore, encompassed a number of out-dated
clinical practices and ignored currently well-established
modalities [29,30,34,42].
Much of the literature on spinal metastasis in thyroid
cancer is based on small sample sized studies. This
makes it difficult to measure the effectiveness of some
treatment modalities and draw conclusions. Additionally,
this makes it difficult to use the data in multivariate ana-
lysis due to the high standard errors, which would occur
with small sample size [14,16,36,40,44,45].
Finally, most countries have specific guidelines and
recommendations for the management of certain can-
cers, including the UK [19]. It was difficult to make
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different ‘successful’ methods in similar situations. This
applied to certain treatments, such as thyroidectomy, or
to dose, such of 131I used [14,16,19,40].
Recommendations
Individual prognosis depends upon age at diagnosis of
spinal metastasis, tumour burden and number of spinal
metastases [29,30,34,42,47]. Early detection is a prognos-
tic factor in spinal metastasis of differentiated thyroid
carcinoma (DTC). This early detection could help pre-
vent dissemination to the spine. The proposed process
of which is outlined in figure 2. Post-surgical 131I abla-
tion, in addition to adjuvant therapy, has been shown to
aid in the early detection of bone metastasis. At this
time, thyroglobulin levels are low, and radiological stud-
ies are often negative [14]. Treatment of metastasis
should be done in a multi-disciplinary fashion and take
into account tumour response, palliation and neuro-
logical function. Recommendations of treatment are illu-
strated in Figure 3.
Radioiodine absorption is a prognostic factor in meta-
static disease. Multivariate analysis expounds the prog-
nostic benefit of complete metastectomy and 131I-
therapy, when applicable. Survival rates in DTC patients
are improved by these interventions [13,34,38,47]. This
is, especially so in those below the age of 45, in whom
bone is the only distant metastasis [34]. We espouse that
therapy should be aggressive, particularly in the young
[34].
Patients below the age of 45 years of age with small
DTC distant metastasis should be treated with radio-
iodine until there is an uptake decline or a cumulative
dose of 600 mCi (22 GBq) reached [30]. Subsequent
courses of radioiodine treatment, at least one year after
initial radioiodine treatment may also be a recommended.
Radioiodine therapy comes with its limitations, how-
ever. Treatment exceeding 600 mCi may be deleterious
to the health. There is a significant increase in salivary
gland dysfunction, cancer and leukaemia in patients. In
patients with continued uptake, a decision to continue
treatment beyond that dose should be considered on a
case-by-case basis, due the risks associated [30].
In patients with non 131I avid disease, or who are 131I
non-responders, other treatment modalities ought to be
evaluated. Such treatments include combination therapy,
SET or small molecules, along with radiotherapy. These
may assuage symptomatic disease. VEGFR is particularly
helpful in 131I non-avid disease. SET and bisphospho-
nates are especially useful modalities in reducing bone
pain [15,16,44,45].
Thyroid cancer pathogenesis and promulgation to the
bone has yet to be fully elucidated despite some novel
research by Torre et al. [53] into the role of angiogenicand lymphangiogenic phenotypes, spread to the verte-
bral column is poorly understood. Dissection of this
journey opens the possibility of intervening to improve
patient survival and reduced morbidity.
Conclusions
There is a need for more histology-specific research in
the field of thyroid carcinoma metastasis. While study
sizes are difficult to control, we believe that there is
room for improvement in study design and in the quan-
tity of research on specific treatment modalities.
To sum up, for a young patient aggressive surgery is
the best first line management. Radioiodine and surgery
is our best combined management. Combination ther-
apy, SET or small molecular inhibitor with radiation is
recommended.
Furthermore, VEGFR is particularly helpful in 131I
non-avid disease. SET and bisphosphonates are useful
modalities in palliation. However, more research is
required into the effect of combination therapies.
Future prospects look towards intersecting the mo-
lecular pathways of tumourigenesis and dissemination.
Indeed, spread to the spine is haematogenous, which
opens an avenue to pursue. At present, surgery is our
most logical solution, but it certainly is not curative, but,
rather, symptom control. Cure is the aim.
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